{
  "slug": "mced-cancer-mortality",
  "file": "mced-cancer-mortality.review.md (shipped review)",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "date": "2026-11-02",
  "level_before": "Γ",
  "level_after": "Γ",
  "confidence_before": "High",
  "confidence_after": "High",
  "pmids_checked": 58,
  "pmids_failed": 0,
  "linked_notices_checked": 6,
  "claims_spot_checked": 22,
  "findings": [
    {
      "id": "S1",
      "severity": "Major",
      "location": "AT A GLANCE causal-role cell; Final score paragraph; rendered page 'What this mechanism does' (ROLE_PLAIN in tools/build_v5_reviews.py)",
      "original": "epiphenomenon / 'This travels alongside the process without causing it or being caused by it.'",
      "corrected": "epiphenomenon (framework step 2: no effect on cancer deaths demonstrated in either direction; not a finding of no effect) / per-case gloss: 'No effect of this screening on cancer deaths has yet been shown in either direction; the label records an unproven link, not a proven absence of effect.'",
      "evidence": "Review states 'neither proves a mortality benefit or a mortality null'; the lay gloss asserts absence of causation. Randomised allocation changed the diagnostic pathway (PMC7619610, DOI 10.1056/NEJMoa2505723: emergency presentations 225 vs 286; round-3 stage IV IRR 0.74, 0.57-0.95). Label follows house convention and does not alter the level; the unqualified gloss misleads lay readers."
    },
    {
      "id": "S2",
      "severity": "Major",
      "location": "Final score Momentum paragraph; extended_scoring_MSD.momentum; SC2 matrix row; Stability trigger",
      "original": "Momentum: Decisive work underway. The registered NHS-Galleri trial (NCT05611632/ISRCTN91431511) remains in prespecified cancer-mortality follow-up; the official trial site states that cancer-death analyses continue and the primary report states that further follow-up is warranted.",
      "corrected": "Momentum: Mechanistic only. NHS-Galleri lists cancer-specific mortality up to 8 years as a prespecified secondary outcome (NCT05611632), and the primary report states that cancer-specific and nested mortality will be analysed at 3 and 6 years after the final trial visit, but also that the trial was not powered for mortality endpoints; after the failed primary endpoint its fixed-sequence plan precludes formal testing of secondary outcomes. This follow-up is informative but cannot by itself decisively cross the SC2 threshold. (SC2 row: append '; the trial was not powered for mortality endpoints.')",
      "evidence": "PMC7619610: 'Cancer-specific and nested mortality will be analyzed at 3 and 6 years after final trial visit as secondary endpoints; the trial was not powered for mortality endpoints'; 'Testing stopped at the first non-significant step'. ClinicalTrials.gov NCT05611632 lists cancer-specific mortality as SECONDARY. The abstract's further-follow-up sentence concerns stage outcomes, not deaths. Official trial page mentions deaths only as a future question. The review's own deciding experiment requires an adequately powered mortality comparison."
    },
    {
      "id": "S3",
      "severity": "Minor",
      "location": "AT A GLANCE headline; FULL REVIEW NHS paragraph; inventory [1]; card [1]",
      "original": "The secondary stage IV ratio was 0.86 (0.74–1.00). / headline: 'its favorable secondary stage IV result requires clinical follow-up'",
      "corrected": "The key secondary stage IV ratio, also among 12 prespecified cancer types, was 0.86 (0.74–1.00); because the fixed-sequence plan stopped at the failed primary endpoint, this result was not formally tested and its interval is unadjusted. The stage IV decrease (341 vs 394 participants) was offset by more stage III cancers (360 vs 287), and a prespecified secondary composite of stage III/IV or fatal cancers across routinely staged types was null (IRR 1.04, 0.97–1.12). / headline: 'a lower stage IV rate in a secondary endpoint that could not be formally tested requires clinical follow-up'",
      "evidence": "PMC7619610: hierarchical plan 'precluded any formal testing of secondary outcomes'; CIs 'should not be used for hypothesis testing'; stage III 360 vs 287; stage IV 341 vs 394; fatal-cancer composite IRR 1.04 (0.97-1.12)."
    },
    {
      "id": "S4",
      "severity": "Minor",
      "location": "Subclaim matrix SC1 row; lay page Key points; SC1 literal Γ hard rule 'In vitro-only'",
      "original": "SC1 'Galleri detects cancer-associated signals before clinical diagnosis' graded Γ for 'the unbridged inference from that diagnostic signal to meaningful clinical benefit'; hard rule: 'Applies to the uncontrolled or cell-only positive support class, with ceiling Γ; it does not upgrade that class or describe the whole source set.'",
      "corrected": "Reword SC1 to the graded proposition ('Galleri-detected signals translate into clinically meaningful earlier diagnosis') or mark detection as demonstrated and descriptive with no causal letter; hard rule: 'Not triggered: SC1 evidence is human prospective screening and randomized-arm diagnostic data; no in vitro-only class is offered.'",
      "evidence": "PMID42773209: 937 MCED-detected primary cancers; PMID37805216: 35 confirmed cancers; no in vitro study assigned to SC1. Lay page prints 'SC1 ... HSEF Γ'. SC1 does not bind the headline; no level change."
    },
    {
      "id": "S5",
      "severity": "Minor",
      "location": "Inventory tally sentence; causal_tally_audit.screened_discriminating_contrasts; evidence_inventory[].discriminating_contrast",
      "original": "Tally: 0 positive qualifying study units across scoped subclaims; 5 screened discriminating contrast units.",
      "corrected": "Tally: 0 positive qualifying study units across scoped subclaims; 4 screened discriminating contrast units, the randomized allocated-arm contrasts [1], [48], [49] and [51]. [45] is an observational pre/post contrast and [2], [10] and [18] are single-arm descriptive series.",
      "evidence": "Score card flags discriminating_contrast true for [1],[10],[18],[45],[51] and false for NLST [48] and NELSON [49]. PATHFINDER and the real-world series have no comparator. Earlier approval's rejected finding (v) mis-describes the set. Positive tally 0 unaffected."
    },
    {
      "id": "S6",
      "severity": "Minor",
      "location": "FULL REVIEW comparator paragraph; inventory [51]; SC3 rationale; Rank 1 and Rank 3 models",
      "original": "UKCTOCS Methods/Results show 47.2% more stage I and 24.5% fewer stage IV ovarian/tubal diagnoses with multimodal screening, while mortality did not fall after 16.3 years",
      "corrected": "... while the combined stage III/IV reduction (10.2%, 95% CI −21.3 to 2.4) was not significant and mortality did not fall after 16.3 years (PMID33991479). Across 41 screening RCTs, reductions in stage III–IV incidence tracked mortality reductions closely for ovarian (ρ 0.99) and lung (ρ 0.92) cancer but weakly for colorectal (ρ 0.39) and prostate (ρ −0.69) cancer (PMID38583868), so stage-surrogate validity is site specific rather than universally absent.",
      "evidence": "PMID33991479 and PMID37183782 report the non-significant stage III/IV change. Feng et al. JAMA 2024, PMID38583868, DOI 10.1001/jama.2024.5814, is the systematic evidence on SC3 and is absent. Supports the site-specific verdict; shows UKCTOCS is a stage IV-only dissociation, the same pattern as NHS-Galleri."
    },
    {
      "id": "S7",
      "severity": "Minor",
      "location": "FULL REVIEW after PATHFINDER paragraph; REFERENCES",
      "original": "(PATHFINDER 2 not cited)",
      "corrected": "PATHFINDER 2 enrolled 35,878 adults aged 50 or older without clinical suspicion of cancer; among 32,007 performance-analyzable participants, detection rate was 0.54%, PPV 60.3%, episode sensitivity 39.3% (69.8% for 12 prespecified cancers), specificity 99.64%, and 213 (0.6%) had invasive procedures after a positive test. Endpoints were descriptive and the authors state that randomized trials and longer follow-up are needed to assess clinical utility (PMID42773207).",
      "evidence": "PMID42773207, Nat Med 22 Sep 2026, DOI 10.1038/s41591-026-04618-w; inside the 2026-10-13 cutoff and cited as concordant by the NHS-Galleri report. Strengthens SC1 and harms record; does not touch SC2."
    },
    {
      "id": "S8",
      "severity": "Minor",
      "location": "final_score.confidence_rationale; reader-summary.json limitations",
      "original": "Fifty-eight primary reports include seven large randomized screening trials (NHS-Galleri 142,250; NLST 53,454; NELSON; UKCTOCS 202,562; NordICC 84,585; CAP 415,357; ERSPC 162,236) and multiple independent MCED assay modalities ... / 'density, heterogeneous controls and incomplete access set the confidence, not correctness.'",
      "corrected": "High reflects that the ceiling is well characterised: a large randomized Galleri trial with registry outcomes, a concordant large prospective study and a real-world series all leave no Galleri mortality contrast, so the evidence securely does not justify more than Γ. Other-site mortality trials inform SC3 and the tournament, not Galleri replication. / 'Confidence reflects evidence density and reproducibility, not access depth or correctness.'",
      "evidence": "Six of seven cited trials are other modalities the review says do not transfer. Framework permits (Γ, High) when confident evidence does not justify more than Γ. High stands. Reader summary retains access-depth wording struck from the score card by the earlier M4."
    },
    {
      "id": "S9",
      "severity": "Minor",
      "location": "Evidence cards [33]-[58]; reader-summary.json; web-page.md; CONSENSUS_CROSSCHECK.md; score card rationale and causal_tally_audit",
      "original": "Referral-enrichedvariantdenominator; does not mean 40% ofall DTCcustomersortestsarewrong; Avoiduncorrectedfinegrainsubgroup CIwhichabstractformatsanegativeupperbound; Gallerioreverycancer; MCEDmortalityevidence; the2026; stageIV; uses142924 enrolled participants aged50–79; The58 report count",
      "corrected": "Referral-enriched variant denominator; does not mean 40% of all DTC customers or tests are wrong; Avoid the uncorrected fine-grain subgroup CI, which the abstract prints with a negative upper bound; Galleri or every cancer; MCED mortality evidence; the 2026; stage IV; uses 142924 enrolled participants aged 50–79; The 58 report count",
      "evidence": "Known renderer defect; earlier M1 claimed every card repaired; ~30 fused tokens remain. NordICC 13-year abstract (PMID42102826) indeed prints '0·77 [0·64 to -0·88]'. No content change."
    },
    {
      "id": "S10",
      "severity": "Minor",
      "location": "COMPETING MECHANISTIC MODELS",
      "original": "Rank 1 'Screening benefit is site, assay, risk and pathway specific' (Ε) is compatible with the nominal; explains_what_nominal_does_not repeats its core claim; no shedding-bias rival.",
      "corrected": "Add rival: 'Shedding-biased detection: cfDNA tests preferentially detect high-shedding, biologically advanced cancers, so detections concentrate where an earlier diagnosis changes outcomes least.'",
      "evidence": "PMID34176681: stage I 16.8% vs stage IV 90.1%; PMID42773209: episode sensitivity 26.7-37.2%; PMC7619610: stage III excess 360 vs 287 and 'cfDNA shedding is a hallmark of more aggressive cancers'. Tournament informs primacy only; no level change."
    },
    {
      "id": "S11",
      "severity": "Editorial",
      "location": "Review header vs score card review_metadata.reviewer, codex-correction-provenance.json, site page attribution; reader-summary redteamReviewed",
      "original": "Header 'Generated by Sol 6.1'; score card and site page 'Codex'; provenance generated_by 'Codex; HSEF v5.3'; redteamReviewed false despite approval section.",
      "corrected": "Reconcile attribution by lead adjudication; set redteamReviewed consistently with the approval state.",
      "evidence": "This log records the authoring model stated in the review header, as instructed; conflict flagged, not resolved."
    }
  ],
  "rejected_findings": [
    "SC2 at Β rather than Γ: argued; randomised allocation produced system-level changes short of mortality and the mechanism has positive precedents elsewhere. Γ holds.",
    "Aggregation: primary-subclaim returns Γ from SC2, matching the headline; weakest-link Α from SC4 is reported only as a sensitivity.",
    "Cancer-stem-cell literal criteria are disclosed as an unchanged rubric quotation with explicit clinical adaptation; not undisclosed template bleed (one misapplied SC1 line raised as S4).",
    "All spot-checked figures matched their sources, including NHS 142,250 randomised vs 142,924 enrolment-paper figure (PMID39862108) and 142,826 consented (PMC7619610).",
    "NLST collective author renders correctly; no collective-author defect.",
    "Stability 'Uncertain' defensible: an underpowered secondary mortality analysis can still constrain the boundary.",
    "Δ block correct: no positive exact-assay cancer-death endpoint exists.",
    "No retraction or expression of concern on any reference; errata 41812212 and 42119586 content not examined in this pass."
  ],
  "earlier_approval_claims_not_sustained": [
    "Rejected finding (v): the five discriminating contrasts are not the allocated-arm subset (see S5).",
    "M1: fused words were not repaired in every evidence card (see S9)."
  ],
  "validator": "not re-run (no file changed in this pass)",
  "scorecard_changed": false,
  "scorecard_changes_proposed": [
    "role_of_mechanism gloss qualifier (S1)",
    "extended_scoring_MSD.momentum value/artifact/justification (S2)",
    "causal_tally_audit.screened_discriminating_contrasts 5->4 and inventory flags (S5)",
    "final_score.confidence_rationale (S8)"
  ],
  "approval": "Not granted in this pass; level and confidence stand, approval should follow correction of S1 and S2.",
  "new_literature_verified": [
    "PMID42773209 PATHFINDER 2, DOI 10.1038/s41591-026-04618-w",
    "PMID38583868 Feng et al. JAMA 2024, DOI 10.1001/jama.2024.5814"
  ],
  "residual_limitations": [
    "NEJM report read from PMC author manuscript PMC7619610, not the version of record; supplementary appendix not examined.",
    "Scite not queried."
  ]
}